{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:12Z","timestamp":1792782972613,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Project of Beijing Medical Award Foundation","award":["YXJL-2022-0187-0013"],"award-info":[{"award-number":["YXJL-2022-0187-0013"]}],"id":[{"id":"https:\/\/ror.org\/03gzgaa54","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Beijing Hongdingxiang Public Welfare Development Center","award":["BJ-HDX-20220437"],"award-info":[{"award-number":["BJ-HDX-20220437"]}]},{"name":"The General Program of Harbin Medical University Cancer Hospital Haiyan Fund","award":["JJMS2022-19"],"award-info":[{"award-number":["JJMS2022-19"]}],"id":[{"id":"https:\/\/ror.org\/01f77gp95","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00280-023-04590-z","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T03:01:41Z","timestamp":1695438101000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer"],"prefix":"10.1007","volume":"93","author":[{"given":"Mengfei","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1235-6269","authenticated-orcid":false,"given":"Shuai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,23]]},"reference":[{"key":"4590_CR1","first-page":"2100","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M (2019) Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study, arthritis. Rheumatol 71:2100\u20132111","journal-title":"Rheumatol"},{"key":"4590_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116\u2013129","journal-title":"Eur J Cancer"},{"key":"4590_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/0091270012445206","volume":"53","author":"J Yang","year":"2013","unstructured":"Yang J, Zhao H, Garnett C, Rahman A, Gobburu JV, Pierce W, Schechter G, Summers J, Keegan P, Booth B, Wang Y (2013) The combination of exposure-response and case-control analyses in regulatory decision making. J Clin Pharmacol 53:160\u2013166","journal-title":"J Clin Pharmacol"},{"key":"4590_CR4","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/cpt.1953","volume":"108","author":"HI Dai","year":"2020","unstructured":"Dai HI, Vugmeyster Y, Mangal N (2020) Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther 108:1156\u20131170","journal-title":"Clin Pharmacol Ther"},{"key":"4590_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.12.008","volume":"109","author":"EA Basak","year":"2019","unstructured":"Basak EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, Bins S, Oomen-de Hoop E, Wijkhuijs AJM, Besten ID, Sleijfer S, Debets R, van der Veldt AAM, Aerts J, Mathijssen RHJ (2019) Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer. Eur J Cancer 109:12\u201320","journal-title":"Eur J Cancer"},{"key":"4590_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","volume":"7","author":"DP Hurkmans","year":"2019","unstructured":"Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop EO, Debets R, Joerger M, Odink A, van der Veldt AAM, van der Leest CH, Aerts J, Mathijssen RHJ, Koolen SLW (2019) A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 7:192","journal-title":"J Immunother Cancer"},{"key":"4590_CR7","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","volume":"24","author":"DC Turner","year":"2018","unstructured":"Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA (2018) Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res 24:5841\u20135849","journal-title":"Clin Cancer Res"},{"key":"4590_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","volume":"44","author":"H Li","year":"2017","unstructured":"Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, de Greef R, Chatterjee M, Kondic AG, Stone JA, Booth BP, Keegan P, Rahman A, Wang Y (2017) Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn 44:403\u2013414","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4590_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jitc-2021-002663","volume":"9","author":"Y Koguchi","year":"2021","unstructured":"Koguchi Y, Iwamoto N, Shimada T, Chang SC, Cha J, Curti BD, Urba WJ, Piening BD, Redmond WL (2021) Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. J Immunother Cancer 9:10","journal-title":"J Immunother Cancer"},{"key":"4590_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/psp4.12406","volume":"8","author":"JJ Wilkins","year":"2019","unstructured":"Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, Bello CL, Neuteboom B, Wade JR, Girard P, Khandelwal A (2019) Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma. CPT Pharmacometrics Syst Pharmacol 8:415\u2013427","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4590_CR11","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/s41401-020-00550-y","volume":"42","author":"CY Wang","year":"2021","unstructured":"Wang CY, Sheng CC, Ma GL, Xu D, Liu XQ, Wang YY, Zhang L, Cui CL, Xu BH, Song YQ, Zhu J, Jiao Z (2021) Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy. Acta Pharmacol Sin 42:1368\u20131375","journal-title":"Acta Pharmacol Sin"},{"key":"4590_CR12","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-17-2439","volume":"24","author":"J Huang","year":"2018","unstructured":"Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D, Qu D, Wang X, Lan B, Yang B, Wang P, Zhang H, Yang Q, Jiao Y (2018) Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res 24:1296\u20131304","journal-title":"Clin Cancer Res"},{"key":"4590_CR13","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1158\/1078-0432.CCR-16-2842","volume":"23","author":"Y Feng","year":"2017","unstructured":"Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B, Finckenstein FG, Park JS, Roy A (2017) Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin Cancer Res 23:5394\u20135405","journal-title":"Clin Cancer Res"},{"key":"4590_CR14","first-page":"101","volume":"9","author":"E Dreesen","year":"2017","unstructured":"Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D (2017) Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol Adv Appl 9:101\u2013111","journal-title":"Clin Pharmacol Adv Appl"},{"key":"4590_CR15","first-page":"1291","volume":"18","author":"S Vermeire","year":"2020","unstructured":"Vermeire S, Dreesen E, Papamichael K, Dubinsky MC (2020) How, when, and for whom should we perform therapeutic drug monitoring? Clin Gastroenterol Hepatol Off Clin Practice J Am Gastroenterol Assoc 18:1291\u20131299","journal-title":"Clin Gastroenterol Hepatol Off Clin Practice J Am Gastroenterol Assoc"},{"key":"4590_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","volume":"131","author":"M Lala","year":"2020","unstructured":"Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Yamamoto N, Siu LL, Chartash E, Aboshady H, Jain L (2020) A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer 131:68\u201375","journal-title":"Eur J Cancer"},{"key":"4590_CR17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ (2019) Camrelizumab: first global approval. Drugs 79:1355\u20131361","journal-title":"Drugs"},{"key":"4590_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","volume":"119","author":"H Mo","year":"2018","unstructured":"Mo H, Huang J, Xu J, Chen X, Wu D, Qu D, Wang X, Lan B, Wang X, Xu J, Zhang H, Chi Y, Yang Q, Xu B (2018) Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer 119:538\u2013545","journal-title":"Br J Cancer"},{"key":"4590_CR19","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-18-1847","volume":"24","author":"CC Coss","year":"2018","unstructured":"Coss CC, Clinton SK, Phelps MA (2018) Cachectic cancer patients: immune to checkpoint inhibitor therapy? Clin Cancer Res 24:5787\u20135789","journal-title":"Clin Cancer Res"},{"key":"4590_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","volume":"24","author":"TR Flint","year":"2016","unstructured":"Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT (2016) Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab 24:672\u2013684","journal-title":"Cell Metab"},{"key":"4590_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/cts.12633","volume":"12","author":"P Baverel","year":"2019","unstructured":"Baverel P, Roskos L, Tatipalli M, Lee N, Stockman P, Taboada M, Vicini P, Horgan K, Narwal R (2019) Exposure-response analysis of overall survival for tremelimumab in unresectable malignant mesothelioma: the confounding effect of disease status. Clin Transl Sci 12:450\u2013458","journal-title":"Clin Transl Sci"},{"key":"4590_CR22","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","volume":"19","author":"Y Feng","year":"2013","unstructured":"Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS (2013) Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 19:3977\u20133986","journal-title":"Clin Cancer Res"},{"key":"4590_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2019.02.017","volume":"114","author":"M Badawi","year":"2019","unstructured":"Badawi M, Coss CC, Phelps MA (2019) Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on \u201ccorrelation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer\u201d by Basak et al. Eur J Cancer 114:25\u201326","journal-title":"Eur J Cancer"},{"key":"4590_CR24","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/bcp.14662","volume":"87","author":"S Kawakatsu","year":"2021","unstructured":"Kawakatsu S, Bruno R, K\u00e5gedal M, Li C, Girish S, Joshi A, Wu B (2021) Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology. Br J Clin Pharmacol 87:2493\u20132501","journal-title":"Br J Clin Pharmacol"},{"key":"4590_CR25","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","volume":"194","author":"M Pyzik","year":"2015","unstructured":"Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS (2015) FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol (Baltimore MD: 1950) 194:4595\u20134603","journal-title":"J Immunol (Baltimore MD: 1950)"},{"key":"4590_CR26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633\u2013659","journal-title":"Clin Pharmacokinet"},{"key":"4590_CR27","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.7150\/jca.49213","volume":"11","author":"L Huang","year":"2020","unstructured":"Huang L, Li L, Zhou Y, Yang Z, Wang M, Gao Y, Yang Y, Yang F, Liu B, Hong X, Chen G (2020) Clinical characteristics correlate with outcomes of immunotherapy in advanced non-small cell lung cancer. J Cancer 11:7137\u20137145","journal-title":"J Cancer"},{"key":"4590_CR28","doi-asserted-by":"publisher","first-page":"20282","DOI":"10.18632\/oncotarget.7943","volume":"7","author":"JM Araujo","year":"2016","unstructured":"Araujo JM, Prado A, Cardenas NK, Zaharia M, Dyer R, Doimi F, Bravo L, Pinillos L, Morante Z, Aguilar A, Mas LA, Gomez HL, Vallejos CS, Rolfo C, Pinto JA (2016) Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. Oncotarget 7:20282\u201320292","journal-title":"Oncotarget"},{"key":"4590_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2016.06.016","volume":"99","author":"K Shien","year":"2016","unstructured":"Shien K, Papadimitrakopoulou VA (2016) Wistuba, II, Predictive biomarkers of response to PD-1\/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 99:79\u201387","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"4590_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12967-019-2101-2","volume":"17","author":"C Li","year":"2019","unstructured":"Li C, Li C, Zhi C, Liang W, Wang X, Chen X, Lv T, Shen Q, Song Y, Lin D, Liu H (2019) Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. J Transl Med 17:355","journal-title":"J Transl Med"},{"key":"4590_CR31","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1158\/0008-5472.CAN-20-3991","volume":"81","author":"X Wang","year":"2021","unstructured":"Wang X, Ricciuti B, Nguyen T, Li X, Rabin MS, Awad MM, Lin X, Johnson BE, Christiani DC (2021) Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer. Can Res 81:2566\u20132573","journal-title":"Can Res"},{"key":"4590_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lungcan.2020.12.027","volume":"152","author":"R Lobefaro","year":"2021","unstructured":"Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, De Braud F, Morgillo F, Garassino MC, Lo Russo G (2021) Immunotherapy in advanced non-small cell lung cancer patients with poor performance status: the role of clinical-pathological variables and inflammatory biomarkers. Lung cancer (Amsterdam, Netherlands) 152:165\u2013173","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"4590_CR33","first-page":"462","volume":"7","author":"ZK Pan","year":"2015","unstructured":"Pan ZK, Ye F, Wu X, An HX, Wu JX (2015) Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis 7:462\u2013470","journal-title":"J Thorac Dis"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04590-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04590-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04590-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:08:31Z","timestamp":1792231711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04590-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["4590"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04590-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,23]]},"assertion":[{"value":"24 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the project number of the Beijing Medical Award Foundation in the Acknowledgements section.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}